Thrombosis and Anticoagulation Therapy in Patients with COVID-19 in Japan Study
Not Applicable
- Conditions
- Coronavirus disease 2019: COVID-19, severe acute respiratory syndrome coronavirus 2: SARS-CoV-2, Thrombosis
- Registration Number
- JPRN-UMIN000045800
- Lead Sponsor
- Fukushima Daiichi Hospital
- Brief Summary
In the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2894
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of thrombosis during the hospitalization
- Secondary Outcome Measures
Name Time Method